Leerink Swann Starts Ambit Biosciences (AMBI) at Outperform
Tweet
Share
E-mailGet Alerts AMBI Hot Sheet
Price: $0.54 --0%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 6
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 6
Join SI Premium – FREE
Leerink Swann initiated coverage on Ambit Biosciences (NASDAQ: AMBI) with an Outperform rating and a price target of $14.00.
Analyst Howard Liang said, "In an area where chemotherapy remains as the standard of care with limited breakthrough, we see AMBI's quizartinib as the best-in-class FLT3 inhibitor which currently represents the mainstay for targeted therapy for acute myeloid leukemia (AML). The Phase III-ready wholly owned asset is expected to deliver data in 2015 while the possibility of filing based on the Phase II data could provide near-term upside to the stock."
For an analyst ratings summary and ratings history on Ambit Biosciences click here. For more ratings news on Ambit Biosciences click here.
Shares of Ambit Biosciences closed at $7.79 yesterday.
Analyst Howard Liang said, "In an area where chemotherapy remains as the standard of care with limited breakthrough, we see AMBI's quizartinib as the best-in-class FLT3 inhibitor which currently represents the mainstay for targeted therapy for acute myeloid leukemia (AML). The Phase III-ready wholly owned asset is expected to deliver data in 2015 while the possibility of filing based on the Phase II data could provide near-term upside to the stock."
For an analyst ratings summary and ratings history on Ambit Biosciences click here. For more ratings news on Ambit Biosciences click here.
Shares of Ambit Biosciences closed at $7.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Starts Jasper Therapeutics (JSPR) at Overweight
- Piper Sandler Starts Mercury Systems (MRCY) at Overweight
- Siemens Ltd. (SIEM:IN) PT Raised to INR3,000 at BofA Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
